Currently available biological agents for the management of RA are anticytokines (anti-TNFα, anti-IL-1β, or anti-IL-6), anticell therapies (anti-B cell, CTLA-4Ig), and signal inhibitors (JAK inhibitors). This evidence concerns the gene TNF and rheumatoid arthritis.